electroCore Inc. (ECOR)
ECOR trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1560258/000149315226011636/0001493152-26-011636-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ECOR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001560258 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $32.0M |
| Net income | -$14.0M |
| Operating income | -$13.2M |
| Net margin | -43.6% |
| Operating margin | -41.1% |
| Revenue growth | +27.2% |
| Cash | $7.0M |
| Total assets | $18.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt regarding the Company's ability to continue as a going concern." | 10-Q 2026-11-04 |
| Cash and burn | $6.3M cash; operating cash flow -$2.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 9,226,006 (2026-10-30); 7,995,903 a year earlier; 6,002,420 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $212K, sold $946K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $9.7M | -$1.3M | -$2.8M | $6.3M | $8.2M | $38.0M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $9.4M | -$3.1M | -$3.5M | $8.5M | $8.8M | $37.0M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $9.6M | -$5.3M | -$3.0M | $4.9M | $8.0M | $34.9M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $9.2M | -$3.0M | -$1.5M | $7.0M | $7.8M | $32.0M | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | $8.7M | -$3.4M | -$1.7M | $7.9M | $7.8M | $29.8M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $7.4M | -$3.7M | -$623K | $3.4M | No debt tags | $27.7M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $6.7M | -$3.9M | -$4.4M | $3.8M | No debt tags | $26.5M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $7.0M | -$3.2M | -$1.3M | $3.7M | No debt tags | $25.2M | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-10-24 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEF 14A | 2026-07-20 |
Source: SEC EDGAR submissions feed, 492 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -27.6% |
| 1 month | -37.4% |
| 3 months | -47.2% |
| Year to date | +17.1% |
| 1 year | -8.1% |
| From 52-week high | -57.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| POCI | Precision Optics Corporation Inc. | $4.97 | -4.97% | $54.6M |
| OM | Outset Medical Inc. | $3.39 | -9.12% | $64.0M |
| HYPR | Hyperfine Inc. | $0.6101 | -3.05% | $64.8M |
| NRXS | Neuraxis Inc. | $4.80 | -11.44% | $68.1M |
| QTI | QT Imaging Holdings Inc. | $1.80 | -4.26% | $26.4M |
| STXS | Stereotaxis Inc. | $0.8027 | -4.80% | $80.4M |
| VANI | Vivani Medical Inc. Common Stock (DE) | $1.02 | +0.99% | $92.0M |
| HSDT | Solana Company Class A Common Stock (DE) | $1.64 | -5.20% | $103.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier